Surgical Mesh And Sling Devices Must Undergo Post-Market Studies
This article was originally published in The Gray Sheet
Executive Summary
FDA sends post-market study orders to 33 manufacturers of urogynecologic surgical mesh used for pelvic organ prolapse and to seven makers of single-incision mini-slings used for stress urinary incontinence.
You may also be interested in...
Boston Scientific’s Sec. 522 Studies On Pelvic Mesh Show It’s Too Risky, FDA Says
The US FDA says final data from two Boston Scientific postmarket studies have reinforced the agency’s position that the company’s transvaginal mesh to treat pelvic organ prolapse (POP) has a poor benefit-risk profile. The firm’s mesh has been off the US market since 2019.
Unlocking Legalities: To Change How Courts View 510(k) Clearances, Industry Seeks 'Supreme' Support
Medtech's legal realm wants the US Supreme Court to correct the record on 510(k)s next term, and they say they've found the right case to make that happen: a J&J/Ethicon mesh device suit where the lower court refused to let the jury hear any mention at all of US FDA or the product's 510(k) clearance. Courts say 510(k)s lack sufficient relevance to support a company's case for product safety, but industry says that view is based on outdated facts and is fundamentally unfair.
FDA Proposes PMAs For Pelvic Organ Prolapse Mesh Devices
FDA is proposing class III, PMA status for surgical mesh used to treat pelvic organ prolapse based on evidence of health risks including mesh exposures and extrusions, pelvic pain, infections and repeat surgery for complications.